Q&A: Revance's New CEO Nadeem Moiz Charts Bold Vision After Crown Acquisition

Medical professional examining facial skin with blue medical gloves
CEO Nadeem Moiz aims to blend innovation, empathy and strategy to elevate the unified Revance brand.
Courtesy of Prostock-studio at Adobe Stock

In February 2025, Crown Laboratories acquired Revance Therapeutics, uniting two leaders in skincare and aesthetics under the Revance name. Following the acquisition, Revance appointed a new chief executive officer, Nadeem Moiz, on Oct. 1 to support its next phase of growth. Moiz, previously president, COO and CFO of the brand succeeds Jeff Bedard, the founder. 

This transition reflects a long-term succession plan as the newly combined company aims to solidify its position as a leader in injectables, skin quality and skincare solutions. Moiz brings over 25 years of experience in strategy, operations and finance—a smooth progression from the role he played in Revance’s recent integration efforts. 

This article is only available to registered users.

Log In to View the Full Article

More in Companies